Shares of JD.com Inc. are up more than 3% in premarket trading Wednesday after Mizuho analyst James Lee upgraded the Chinese e-commerce giant's stock to buy from neutral, writing of "significant opportunities in online pharmacy and pull-forward effects in essentials from COVID-19." He is upbeat about Chinese government reform of the retail pharmacy industry that is looking to move medicine sales away from hospitals and clinics and toward retail stores. Lee estimates a total addressable market of RMB 2 trillion ($282 billion). He also expects that the COVID-19 crisis has "accelerated" online demand for home essentials, which could continue benefitting JD as Lee says that demand for such products "has not declined that much" even as China has begun its return to normal. Lee upped his price target on the stock to $58 from $37. JD shares have added 12% over the past three months as the KraneShares CSI China Internet ETF has lost 5.2%. Source Marketwatch
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.